Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016

  • ID: 3788896
  • Report
  • 79 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Immune Design Corp.
  • ImmunoFrontier, Inc.
  • Kite Pharma, Inc.
  • MORE
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016

Summary

‘Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016’, provides in depth analysis on Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
- The report reviews Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Immune Design Corp.
  • ImmunoFrontier, Inc.
  • Kite Pharma, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) Overview

Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine. Therapeutics Development

Therapeutics Development

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Stage of Development

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Therapy Area

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Indication

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Companies

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Products under Development by Universities/Institutes

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Companies Involved in Therapeutics Development

Aduro BioTech, Inc.

Boehringer Ingelheim GmbH

Celldex Therapeutics, Inc.

GlaxoSmithKline Plc

Immune Design Corp.

ImmunoFrontier, Inc.

Kite Pharma, Inc.

Sanofi Pasteur SA

Scancell Holdings Plc

Vault Pharma Inc.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Drug Profiles

ADU-623 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

G-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2241658A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMF-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-65 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LV-305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCIB-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Acute Myeloid Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCP-2292 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPI-111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Dormant Projects

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Discontinued Products

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Featured News & Press Releases

Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate LV305 at ASCO

Jun 08, 2016: Immune Design Announces Updated Results For Immuno-oncology Product Candidate CMB305 At ASCO

Jun 04, 2016: Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses in Patients with Melanoma

Apr 21, 2016: Immune Design Announces Presentation on LV-305 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 18, 2016: Celldex Therapeutics Presents Poster on CDX-1401 at the AACR Annual Meeting 2016

Feb 09, 2016: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trial of CMB305

Jan 08, 2016: Immune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305

Nov 11, 2015: Immune Design Announces Start of Randomized Phase 2 Cancer Immunotherapy Combination Trial in Patients With Soft Tissue Sarcoma

Aug 12, 2015: Immune Design Announces Phase 2 Cancer Immunotherapy Trial Collaboration

Jun 01, 2015: Aduro Biotech Announces ASCO Presentation of Encouraging Data From Ongoing Phase 1b Clinical Trial of Its Immunotherapy for the Treatment of Mesothelioma

May 13, 2015: Immune Design Announces Positive Data from Phase 1 Studies On LV305 at the 2015 American Society of Clinical Oncology Annual Meeting

May 13, 2015: Immune Design To Present Positive Phase 1 Data From On G305 at the 2015 American Society of Clinical Oncology Annual Meeting

Mar 31, 2015: Immune Design Announces Positive Topline Data From Phase 1 Clinical Trials of Immuno-Oncology CMB305 Agent

Mar 26, 2015: Immune Design Announces Treatment of Patients With CMB305 Investigational Immuno-Oncology Agent

Jun 05, 2014: Immune Design Announces Treatment of First Patient in Phase 1 Clinical Trial of LV305 Immuno-Oncology Agent

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 79List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Aduro BioTech, Inc., H1 2016

Pipeline by Boehringer Ingelheim GmbH, H1 2016

Pipeline by Celldex Therapeutics, Inc., H1 2016

Pipeline by GlaxoSmithKline Plc, H1 2016

Pipeline by Immune Design Corp., H1 2016

Pipeline by ImmunoFrontier, Inc., H1 2016

Pipeline by Kite Pharma, Inc., H1 2016

Pipeline by Sanofi Pasteur SA, H1 2016

Pipeline by Scancell Holdings Plc, H1 2016

Pipeline by Vault Pharma Inc., H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Discontinued Products, H1 2016 64List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aduro BioTech, Inc.
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline Plc
  • Immune Design Corp.
  • ImmunoFrontier, Inc.
  • Kite Pharma, Inc.
  • MORE
Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) pipeline Target constitutes close to 15 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report CancerTestis Antigen 1 – Pipeline Review, H1 2016, outlays comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) Cancer/Testis Antigen 1 is a protein encoded by CTAG1A gene is an antigen that is over expressed in many cancers but that is also expressed in normal ovary and testis tissues which makes it a good candidate for a cancer vaccine. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 6, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aduro BioTech, Inc.
Boehringer Ingelheim GmbH
Celldex Therapeutics, Inc.
GlaxoSmithKline Plc
Immune Design Corp.
ImmunoFrontier, Inc.
Kite Pharma, Inc.
Sanofi Pasteur SA
Scancell Holdings Plc
Vault Pharma Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll